For the roughly one million Americans living with Parkinson’s disease, every approved treatment does the same thing: manage symptoms. None slows the underlying brain degeneration. Results published in April 2026 in Nature Medicine suggest an experimental drug called BIIB094 could eventually change that, after a Phase 1 trial showed it cut levels of a key disease-linked protein by up to 59% in patients’ cerebrospinal fluid.
BIIB094 is an antisense oligonucleotide, a short strand of synthetic genetic material designed to intercept the molecular instructions cells use to build a specific protein. In this case, the target is LRRK2 (pronounced “lark two”), an enzyme that has been implicated in Parkinson’s for more than a decade. Mutations in the LRRK2 gene are the most common known genetic cause of the disease, responsible for up to 5% of familial cases and roughly 1 to 2% of all diagnoses, with especially high rates among Ashkenazi Jewish and North African Berber populations.
The drug was developed by Biogen in collaboration with Ionis Pharmaceuticals. The trial results mark the first controlled human evidence that an antisense therapy can substantially reduce LRRK2 inside the central nervous system.
What the REASON trial found
The trial, registered as NCT03976349 and known as REASON, enrolled 82 adults with Parkinson’s disease across multiple centers. Participants were randomized to receive BIIB094 (also called ION859) or placebo in two segments: one testing single ascending doses and the other testing multiple ascending doses. The drug was delivered intrathecally, meaning injected directly into the spinal fluid through a lumbar puncture, so it could bypass the blood-brain barrier and reach the brain far more effectively than a pill taken by mouth.
At the highest dose levels, LRRK2 protein in cerebrospinal fluid dropped by approximately 59%. A second biomarker called pRab10, which reflects how actively LRRK2 is driving enzymatic reactions inside cells, fell by roughly 50%. That second number matters: it indicates the drug did not simply clear protein from the spinal fluid but also dampened the biological chain reaction LRRK2 sets in motion.
Together, those two reductions demonstrate what scientists call target engagement, the clearest proof that a drug is hitting its intended mark inside the body. “This is a critical step,” said Danielle Larson, MD, a study co-author at Northwestern University’s Feinberg School of Medicine, who helped frame the significance of confirming both protein reduction and downstream activity suppression in the same trial. Without that dual confirmation, any later-stage trial testing whether patients actually feel better would be built on shaky ground.
The trial’s primary endpoints were safety, tolerability, and pharmacokinetics. Researchers reported no serious safety concerns, though the small sample size and limited follow-up period mean longer-term risks remain unknown.
Why LRRK2 became a target
The scientific case for going after LRRK2 with antisense oligonucleotides traces back to preclinical work published in Molecular Therapy – Nucleic Acids. In a Parkinson’s mouse model, the approach reduced clumps of alpha-synuclein, the misfolded protein that forms the toxic deposits found in the brains of most Parkinson’s patients. The fact that lowering LRRK2 appeared to limit alpha-synuclein aggregation gave researchers a biological rationale strong enough to justify moving into human testing.
The REASON trial’s biomarker results now provide the first human data point supporting that preclinical logic. But animal findings do not reliably predict what will happen in people, and no one has yet shown that reducing LRRK2 in human cerebrospinal fluid leads to less alpha-synuclein pathology in the brain.
What the trial did not answer
The biggest open question is whether cutting LRRK2 protein actually translates into slower disease progression or meaningful symptom relief. The REASON trial was not designed to measure clinical outcomes like motor function, tremor severity, or quality of life. No patient-reported outcome data have been publicly detailed. A drug can hit its target perfectly and still fail to change the course of a disease.
Long-term safety is another gap. Phase 1 trials typically observe patients over relatively short windows, and the effects of repeated lumbar punctures and intrathecal injections over months or years have not been established for BIIB094. Each dose requires a spinal tap, a procedure that carries discomfort and procedural risks. Whether patients and clinicians will accept that burden over the long haul depends heavily on how strong the eventual efficacy signal turns out to be.
There is also the question of which patients stand to benefit most. LRRK2 mutations drive only a fraction of Parkinson’s cases. Whether lowering LRRK2 helps the majority of patients, those without LRRK2 mutations, is not settled by this trial. The REASON study enrolled adults with Parkinson’s broadly, according to its registry entry, but subgroup analyses by genetic status have not been detailed in the public record.
No official timeline or confirmed endpoints for a Phase 2 or Phase 3 trial of BIIB094 have been publicly announced as of May 2026.
A crowded and competitive field
BIIB094 is not the only approach aimed at LRRK2. Small-molecule kinase inhibitors, which block LRRK2’s enzymatic activity while leaving the protein itself intact, have moved further along in development. Biogen and Denali Therapeutics are testing one such inhibitor, BIIB122 (also known as DNL151), in the Phase 3 LIGHTHOUSE trial. The two strategies are fundamentally different: antisense oligonucleotides reduce the total amount of LRRK2 protein, while kinase inhibitors leave the protein in place but try to shut off its harmful activity.
Whether one approach proves superior is an active area of scientific debate, and no head-to-head data exist. It is possible that both strategies work, that one works better in certain patient populations, or that neither delivers the clinical benefit researchers hope for. The field will not have clear answers until larger and longer trials read out results.
Where this leaves patients and researchers
The REASON trial establishes that BIIB094 can be delivered safely in the short term, reach the central nervous system, and substantially lower both LRRK2 protein and a downstream marker of its activity in human cerebrospinal fluid. That is a meaningful proof of concept for a drug class that had only been validated in animals before.
But proof of concept is not proof of efficacy. Until larger trials demonstrate that reducing LRRK2 slows neurodegeneration, improves movement symptoms, or extends the time before patients need more intensive care, BIIB094 remains a promising experimental strategy rather than a proven treatment. For the Parkinson’s community, the results are a reason for cautious optimism and a signal that the next round of trials will be the ones that truly matter.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
